Bristol Myers Squibb (BMY) Current Deferred Revenue (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Current Deferred Revenue for 18 consecutive years, with $156.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Deferred Revenue fell 23.15% year-over-year to $156.0 million in Q2 2026; TTM through Jun 2026 was $156.0 million, a 23.15% decrease from a year earlier, with the FY2025 full-year figure at $175.0 million, down 21.17% from the prior year.
• Current Deferred Revenue was $156.0 million for Q2 2026 at Bristol Myers Squibb, down from $168.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $326.0 million in Q1 2022 and troughed at $156.0 million in Q2 2026.
• A 5-year average of $249.7 million and a median of $255.5 million in 2024 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue decreased 3.68% in 2023 and slipped 23.15% in 2026, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $289.0 million in 2022, then declined by 5.19% to $274.0 million in 2023, then decreased by 18.98% to $222.0 million in 2024, then declined by 21.17% to $175.0 million in 2025, then dropped by 10.86% to $156.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $156.0 million (Q2 2026), $168.0 million (Q1 2026), and $175.0 million (Q4 2025), per Business Quant data.